London, United Kingdom, May 8, 2024 – MultiOmic Health, a precision medicine discovery venture focused on diabetic cardiorenal complications, is excited to announce its participation in the Bio€quity Europe 2024 conference. The event will be held from May 12 to May 14, 2024, at the Kursaal Congress Center.
Presentation Details:
* Presenter: Robert Thong, CEO at MultiOmic Health
* Presentation Time: May 14, 2024, 14:20 CEST
* Location: Room 4+5, Kursaal Congress Center, San Sebastián, Spain
In his presentation, Robert Thong will share insights into MultiOmic Health’s latest advancements in addressing cardiorenal complications associated with diabetes. Attendees can expect to learn about the company’s innovative approach to precision medicine and its potential to revolutionise patient care.
Robert Thong and Celia Antonio Schell (COO) will also be available for one-on-one meetings throughout the conference.
For more information or to schedule a meeting, please contact us at bdteam@multiomic.health.
About MultiOmic Health
MultiOmic Health is an AI-enabled drug discovery (AIDD) company dedicated to developing novel treatments for metabolic syndrome-related conditions, the world’s largest healthcare burden. It partners with research collaborators across the UK NHS and continental Europe to source de-identified clinical records and patient bio-samples for precision medicine discovery. MultiOmic’s MOHSAIC® platform combines integrated multi-omics analysis and computational systems biology modelling with targeted wet laboratory experiments. Defined patient subpopulations with distinct clinical phenotypes and multi-omics signatures are used to originate novel precision therapeutic concepts that will lead to smaller and shorter clinical trials with higher success rates compared to historical programmes in this disease space. MultiOmic subsequently partners with established biopharma companies to take its therapeutic concepts into global clinical trial programmes and market the ensuing medicines. Its experienced leadership team blends commercial, technical and operational expertise from across the pharma, systems biology and AI/big data arenas.
All participant information provided to MultiOmic by its research collaborators is de-identified, fully consented and in compliance with relevant privacy and data protection legislation, regulations and guidance, including but not limited to the General Data Protection Regulation (GDPR) in both the European Union and the United Kingdom.
